Study details
Enrolling now
An Extension Study for Patients Previously Enrolled in Studies With Pelabresib
Novartis Pharmaceuticals
NCT IDNCT06401356ClinicalTrials.gov data as of Apr 2026
Phase
Phase 3
Target enrollment
50
Study length
about 2.9 years
Ages
18+
Locations
6 sites in CA, FL, IL +2
About this study
Researchers are testing the long-term safety and clinical benefit of pelabresib in people with hematological or solid tumors. The trial also includes patients who previously took pelabresib, either on a placebo or because they stopped taking it for other reasons, to see if it improves survival.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Pelabresib
PhasePhase 3
Primary goalDuration of Response (DoR)
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low10%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Endpoints
Primary: Duration of Response (DoR), Progression-free survival (PFS), Treatment-emergent adverse events (TEAEs) and serious TEAEs
Body systems
Oncology